Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celsus
Cambridge, Massachusetts, United Statescelsiustx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CEL383 (anti-TREM1 antibody) showed safety, tolerability, and favorable pharmacokinetics in healthy volunteers (Phase 1 completed). No Phase 2/efficacy data publicly available as of acquisition.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Monoclonal antibodyCell therapyBiologic
- Industry
- Biotech
02
Partnerships
JanssenServierUniversity of OxfordCleveland ClinicLMU University Hospital MunichParker Institute for Cancer ImmunotherapyInstitut Gustave RoussyUniversity Health Network
Beyond the preview
Go deeper on Celsus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celsus.